A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis

Phase 2 Active not recruiting 21 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This phase 2 study is being conducted to evaluate the efficacy, safety and pharmacokinetics of SHR-1139 in patients with moderate to severe active ulcerative colitis. This study consists 2 treatment parts, the Induction treatment part and Maintenance treatment part. The periods of Induction treatment part and Maintenance treatment part are 12 weeks and 48 weeks separately.

Timeline

Start: 2025-12-01
Primary completion: 2027-08
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1139	Unknown	—	Intravenous

Indications

No indication recorded.